The UK and US have forged a significant bilateral deal that will guarantee no duties on UK drug shipments going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to boost funding on pharmaceuticals through the public health system. This commitment ensures that duties on these vital products will be held at nothing for a duration of 36 months.
This agreement follows earlier statements to significantly raise duties on patented pharmaceutical imports, with potential rates mentioned as high as 100%.
"This agreement with the United Kingdom reinforces the global environment for cutting-edge drugs and brings much-needed balance to U.S.–U.K. drug exports," a release declared.
Commercial Impact
Medicines are one of the UK's largest export categories to the US, which is by far the largest destination for major British pharmaceutical firms.
Statistics indicate that in the one-year period to the end of September, the UK sold medicines valued at £11.1bn to the US. This value accounted for 17.4% of British export trade in that span.
"This guarantee protects work, increases funding and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement includes several notable pledges from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds exceeded 20%.
Industry Background
This agreement takes place against a long-running tension between the sector and the ministers over spending levels and regulatory access.
This friction were intensified by assertions that US consumers were paying a premium for the equivalent treatments than people in the UK and Europe.
In recent months, several large drug company projects in the UK have been paused or cancelled, while major investments have been announced toward American operations.
One official acknowledged that the NHS must increase expenditure on drugs, noting that its spending on drugs had shrunk as a percentage of its resources over the last ten years.
